Chemotherapy for advanced hormone refractory prostate cancer.
about
Chemotherapy for hormone-refractory prostate cancerDefects in death-inducing signalling complex formation prevent JNK activation and Fas-mediated apoptosis in DU 145 prostate carcinoma cellsJNK regulates HIPK3 expression and promotes resistance to Fas-mediated apoptosis in DU 145 prostate carcinoma cellsChemosensitivity assay in mice prostate tumor: Preliminary report of flow cytometry, DNA fragmentation, ion ratiometric methods of anti-neoplastic drug monitoringUse of the aromatase inhibitor anastrozole in the treatment of patients with advanced prostate carcinoma.The diffusion of docetaxel in patients with metastatic prostate cancerDelphinidin sensitizes prostate cancer cells to TRAIL-induced apoptosis, by inducing DR5 and causing caspase-mediated HDAC3 cleavage.Therapeutic options in androgen-independent prostate cancer: building on docetaxel.AR function in promoting metastatic prostate cancerAnisomycin activates JNK and sensitises DU 145 prostate carcinoma cells to Fas mediated apoptosis.Sensitizing cancer cells to TRAIL-induced death by micellar delivery of mitoxantrone.Bicalutamide-activated oncolytic adenovirus for the adjuvant therapy of high-risk prostate cancer.Tranilast inhibits hormone refractory prostate cancer cell proliferation and suppresses transforming growth factor beta1-associated osteoblastic changes.Bisphosphonate induces apoptosis and inhibits pro-osteoclastic gene expression in prostate cancer cells.Melatonin reduces prostate cancer cell growth leading to neuroendocrine differentiation via a receptor and PKA independent mechanism.Specific pomegranate juice components as potential inhibitors of prostate cancer metastasis.Androgen receptor variants: another twist in the plot.Metastasizing, Luciferase Transduced MAT‑Lu Rat Prostate Cancer Models: Follow up of Bolus and Metronomic Therapy with Doxorubicin as Model Drug.Pro-survival function of Akt/protein kinase B in prostate cancer cells. Relationship with TRAIL resistance.Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer.Vinorelbine and estramustine in androgen-independent metastatic prostate cancer: a phase II study.Weekly paclitaxel plus estramustine combination therapy in hormone-refractory prostate cancer: a pilot study.Chemohormonal therapy as primary treatment for metastatic prostate cancer: a randomized study of estramustine phosphate plus luteinizing hormone-releasing hormone agonist versus flutamide plus luteinizing hormone-releasing hormone agonist.Synergistic inhibitory effect of high-intensity focused ultrasound combined with chemotherapy on Dunning adenocarcinoma.Enhancement of cisplatin cytotoxicity by Retigeric acid B involves blocking DNA repair and activating DR5 in prostate cancer cells.The relationship between prostate-specific antigen and TNM classification or Gleason score in prostate cancer patients with low prostate-specific antigen levels.Molecular mechanism of R-bicalutamide switching from androgen receptor antagonist to agonist induced by amino acid mutations using molecular dynamics simulations and free energy calculation.Traditional Chinese Medicine CFF-1 induced cell growth inhibition, autophagy, and apoptosis via inhibiting EGFR-related pathways in prostate cancer.
P2860
Q24243797-DCD0930C-A346-45BB-93C0-8F4E3D8ADC7FQ24299590-7AC25B54-F7FE-497E-BFFA-6F69FA045BC4Q24307612-0FEA3D1D-9288-444C-8B19-F40CD2571817Q24798547-E90D8D9A-7FB7-455A-8ADB-3B1EF3E2EDCBQ30308047-C888312E-FA59-4DE9-8AEA-7829133AA1CBQ35078581-60B35858-6BF3-4E65-A870-E7B338ADC284Q35833213-341D57BD-7029-4C57-9DB9-2D62B4898293Q36344219-6D01FC6B-DEB1-43A0-B1D4-828DD9E9B24DQ38178555-A5C2FE76-0738-41E7-AC70-E52C85BBB063Q38290909-F384FB65-8323-478C-8CB0-409BCCB5260AQ39066649-4293AE0E-7277-4EDD-B332-31C14DE8B3D6Q39139906-1265C0C7-E0C2-4787-AB71-7BF7C94FC9FCQ39852808-75E39B77-E934-46AA-A8EE-3C01FD919FA9Q40268466-6568E132-5138-45DF-8FB7-5407E5BE46D4Q40513840-ED1F40BD-919C-455F-848B-F21863C65E6DQ42170228-34E9A286-1CCE-4655-B453-18DBF0B88AFBQ42371309-E91105E6-B32D-4D0A-A738-FD79CFF212CAQ42576985-877FA596-D69D-4E06-B94B-6FE3D926AD33Q43680908-F41A5F3C-6025-46FE-8A85-D20F7A1860D2Q43761459-FC3FF838-E6D3-43D3-9DF5-BE51759AE78FQ43781929-8138E2F8-5D5A-441A-85A1-464D44095EB2Q44563473-5B6A6994-24CA-4382-BBE1-D62478AB7026Q44713955-5FE5C271-AD09-4DA5-8FE8-A5A51E5CD0D8Q46407845-BF61CA6D-132D-45B7-8A28-ADA6B644153BQ49479651-DF788130-C3C8-4FDB-905F-4AE43E3A3063Q50580241-89B45CC9-A502-438D-8EAE-28BA9A261C11Q51325445-27A8DD63-C0CD-4727-A396-30D6605B63B5Q52658477-2B40564C-41D3-4B88-8EFF-D73D78E5B071
P2860
Chemotherapy for advanced hormone refractory prostate cancer.
description
1999 nî lūn-bûn
@nan
1999 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Chemotherapy for advanced hormone refractory prostate cancer.
@ast
Chemotherapy for advanced hormone refractory prostate cancer.
@en
type
label
Chemotherapy for advanced hormone refractory prostate cancer.
@ast
Chemotherapy for advanced hormone refractory prostate cancer.
@en
prefLabel
Chemotherapy for advanced hormone refractory prostate cancer.
@ast
Chemotherapy for advanced hormone refractory prostate cancer.
@en
P1433
P1476
Chemotherapy for advanced hormone refractory prostate cancer.
@en
P2093
Petrylak DP
P356
10.1016/S0090-4295(99)00452-5
P407
P433
P577
1999-12-01T00:00:00Z